Internal Medicine, Endocrinology, Diabetes, & Metabolism · Greenville, NC
NPI
1649297722
Since 2006
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
1
Medicare group memberships
Hospitals
1
Hospital affiliations
1006 Wh Smith Blvd
Greenville, NC, 27834
Phone (252) 413-6683
Groups this clinician bills Medicare through
Medicare paid, 2024
$577K
28,326 services
Medicare patients, 2024
742
Average age 74
Drug cost, 2024
$2.4M
5,992 prescriptions
Company payments, 2025
$1,094
From 15 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Regina Dodis was code J0897 (injection, denosumab, 1 mg), 4,684 times for 46 patients. In total Regina Dodis billed 28,326 services in 105 codes, and Medicare paid $577K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2015-06-29.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0897 Injection, denosumab, 1 mg | Office | 4,684 | 46 | $19.37 | $91K |
| 99214 Office E&M - Established | Office | 705 | 361 | $88.95 | $63K |
| 83036 Blood Count | Office | 383 | 204 | $9.50 | $3,639 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 355 | 246 | $12.19 | $4,328 |
| 36415 Venipuncture Blood Collection | Office | 337 | 220 | $8.65 | $2,915 |
| 82962 Clinical Chemistry | Office | 304 | 175 | $3.21 | $975 |
| 77080 Standard X-ray | Office | 293 | 293 | $16.62 | $4,871 |
| 84443 Clinical Chemistry | Office | 278 | 176 | $16.43 | $4,567 |
| 84439 Clinical Chemistry | Office | 245 | 160 | $8.78 | $2,151 |
| 84481 Clinical Chemistry | Office | 241 | 158 | $16.48 | $3,972 |
| 95251 Test - Miscellaneous | Office | 206 | 101 | $25.69 | $5,291 |
| 99457 E&M - Miscellaneous | Office | 159 | 36 | $36.20 | $5,756 |
| 80053 Clinical Chemistry | Office | 129 | 104 | $10.23 | $1,320 |
| 96372 Injection Administration | Office | 124 | 55 | $10.02 | $1,243 |
| 82306 Clinical Chemistry | Office | 123 | 95 | $28.81 | $3,544 |
By year: 2022 $387K for 28,415 services; 2023 $356K for 31,017 services; 2024 $577K for 28,326 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 83036 Blood Count | 383 | 204 | $9.50 | $3,639 |
| 36415 Venipuncture Blood Collection | 337 | 220 | $8.65 | $2,915 |
| 82962 Clinical Chemistry | 304 | 175 | $3.21 | $975 |
| 84443 Clinical Chemistry | 278 | 176 | $16.43 | $4,567 |
| 84439 Clinical Chemistry | 245 | 160 | $8.78 | $2,151 |
| 84481 Clinical Chemistry | 241 | 158 | $16.48 | $3,972 |
| 80053 Clinical Chemistry | 129 | 104 | $10.23 | $1,320 |
| 82306 Clinical Chemistry | 123 | 95 | $28.81 | $3,544 |
| 85025 Blood Count | 80 | 64 | $7.51 | $601 |
| 83970 Clinical Chemistry | 51 | 40 | $40.45 | $2,063 |
Medicare prescription drug claims, 2024
In 2024, the drug Regina Dodis prescribed most often to Medicare patients was Levothyroxine Sodium, with 583 prescriptions and refills. In total Regina Dodis wrote 5,992 Medicare prescriptions that cost $2.4M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Levothyroxine Sodium Generic | 583 | 1,293 | 133 | $6,774 |
| Ozempic Semaglutide | 365 | 439 | 60 | $410K |
| Synthroid Levothyroxine Sodium | 231 | 499 | 53 | $20K |
| Methimazole Generic | 203 | 476 | 51 | $1,471 |
| Omnipod 5 Dexg7g6 Pods (Gen 5) Insulin Pump Cart,auto,bt,g6/7 | 178 | 350 | 43 | $247K |
| Gabapentin Generic | 156 | 273 | 36 | $2,542 |
| Glipizide Er Glipizide | 122 | 256 | 32 | $2,026 |
| Metformin Hcl Er Metformin Hcl | 121 | 291 | 34 | $1,522 |
| Novolog Flexpen Insulin Aspart | 117 | 163 | 30 | $35K |
| Metformin Hcl Generic | 112 | 307 | 30 | $2,051 |
| Tresiba Flextouch U-100 Insulin Degludec | 110 | 151 | 27 | $66K |
| Jardiance Empagliflozin | 103 | 162 | 26 | $85K |
| Toujeo Solostar Insulin Glargine,hum.Rec.Anlog | 94 | 170 | 25 | $67K |
| Nano 2nd Gen Pen Needle Pen Needle, Diabetic | 92 | 180 | 34 | $11K |
| Humalog Kwikpen U-100 Insulin Lispro | 86 | 119 | 25 | $29K |
Brand drugs: 2,769 claims; generic drugs: 2,625 claims; opioid claims: 27.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Regina Dodis $1,094 ($1,094 in general payments such as food, travel and fees) from 15 companies. The largest payer was Sequel Med Tech, LLC with $201.
| Company | Payments | Amount |
|---|---|---|
| Sequel Med Tech, LLC | 2 | $201 |
| Ascendis Pharma Endocrinology Inc ASND | 5 | $191 |
| Bayer Healthcare Pharmaceuticals Inc. BAYN.DE | 1 | $109 |
| Recordati_rare_diseases_inc. | 1 | $109 |
| CeQur Corporation | 1 | $103 |
| Corcept Therapeutics CORT | 3 | $73.86 |
| Averitas Pharma Inc. | 2 | $65.08 |
| Neurocrine BioSciences, Inc. NBIX | 2 | $61.81 |
| Amneal Pharmaceuticals LLC AMRX | 2 | $39.37 |
| Tolmar, Inc. | 2 | $34.94 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.